Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 02, 2024 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that Thijs Spoor, the Company’s Chief Executive...
December 12, 2023 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Divests Brachytherapy Business

SEATTLE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced it agreed to fully divest its brachytherapy...
December 07, 2023 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors

First U.S. patient with refractory or relapsed SSTR2-positive neuroendocrine tumors treated with [212Pb]VMT-α-NETPreliminary data readout expected in second half of 2024 SEATTLE, Dec. 07, 2023 ...
November 28, 2023 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Announces First Ever Human SPECT Imaging of Pb-212 with VMT-α-NET by Clinical Collaborators in Germany

Imaging was conducted as part of a clinical study at Technical University of Dresden in GermanyImage was selected as “Image of the Month” in the European Journal of Nuclear Medicine and Molecular...
November 27, 2023 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

SEATTLE, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced the publication of four preclinical studies in support of the Company’s...
November 16, 2023 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Completes Initial Dose Escalation Cohort for Second Novel Targeted Alpha Therapy

SEATTLE, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced the completion of cohort 1 dosing in the Phase 1/2a clinical trial of...
November 14, 2023 16:25 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

SEATTLE, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced third quarter financial results for the period ended September 30, 2023 and provided...
November 08, 2023 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Study of [(212)Pb]VMT-α-NET for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that the first patient was dosed at Washington...
October 16, 2023 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma

SEATTLE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the completion of recruitment for the first patient...
October 10, 2023 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics’ VMT-α-NET Protocols Presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium

SEATTLE, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that two upcoming investigator-initiated trials...